Navigator: Avapritinib (BLU-285)
NAVIGATOR: Avapritinib (BLU-285)
Phase I study of Avapritinib (formerly BLU-285) in patients with GIST and other relapsed/refractory solid tumors (Navigator).
| Trial name: | Navigator |
| Agents: | Avapritinib (formerly BLU-285) |
| Phase | I |
| Status | Completed |
| Sponsor | Blueprint Medicines Corporation |
Further information: https://www.clinicaltrials.gov/ct2/show/NCT02508532?term=NCT02508532&rank=1
WHO is the trial for? |
|
WHAT is the key question that this trial is attempting to answer? |
This study assesses the safety and tolerability, but also the efficacy of avapritinib (BLU-285) in patients with unresectable GIST. This includes patients with a D842V mutation in the PDGFRA gene or those without that mutation which have progressed under at least two different TKI inhibitors. |
WHY patients might want to participate? |
This clinical trial offers patients an opportunity to access a new therapy strategy. This trial will further support the research in GIST and potentially help other patients with this disease. The trial might or might not have benefit in your individual case. |
WHEN will the trial be open? |
The study is active, but not recruiting patients any more. |
WHERE is the trial available? |
The trial is available in several study centers in the US, Belgium, France, Germany, Korea, the Netherlands, Poland, Italy, Spain and the UK. For further information please check here. Study contact: |
STUDY DESIGN: What does the study look like? |
This study just contains one arm: All patients receive the study drug avapritinib (BLU-285). However, the study consists of 2 parts: Part 1 evaluates the dosage in which avapritinib should be given (completed), part 2 the efficacy of the drug. In part 2 there are three different groups (cohorts) being evaluated: patients with PDGFRA D842V-mutant GIST, patients with GIST who received imatinib and at least one other drug and patients who don’t tolerate imatinib or have progressed on it and did not receive any other kind of therapy.
|
HOW do I get more information? |
Patient organisations supporting GIST and/or sarcoma patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving GIST and/or sarcoma patients. If there are no such organisation in your country, please email us for more information: info@sarcoma-patients.eu |
SHARE your experience |
You want to share your experience on this trial? Send us an e-mail to: info@sarcoma-patients.eu Note that your experience would be helpful for other patients and patient organisations. |
RESULTS of the study |
Latest published results were presented during the Annual Conference of the Connective Tissue Oncology Society (CTOS) in November 2017 and can be viewed here. |
Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.